english

China’s Sinovac eying vaccine production site in South Africa, says local partner

Numolux Group, the South African partner of China’s Sinovac Biotech, has said the Chinese firm is in talks about creating a Covid-19 vaccine production site in Africa, as it launches a phase-three trial for use in children.

On Friday, Hilton Klein, the CEO of Numolux Group, said that Sinovac Biotech was eying the creation of a production site in South Africa for the production of Covid-19 vaccines and more. 

“This clinical trial is a precursor to the establishment of a South African vaccine manufacturing facility partnered by Sinovac and Numolux Group that will cover the entire spectrum of vaccinations beyond just the Covid-19 response,” Klein told a news conference.

He said that the vaccine manufacturing facility would be limited to bottling and labelling, allowing the Chinese firm to get vaccines out to the people of Africa as soon as possible. “Vaccines in Africa for Africa,” he added.

Also on rt.com

FILE PHOTO. A health worker prepares a dose of the Anhui Zhifei Longcom Covid-19 coronavirus vaccine in Shenyang, in China's northeastern Liaoning province on May 21, 2021. © AFP / STR
Chinese three-dose vaccine 82% effective against severe Covid-19 infection, developer says

Klein was speaking at the launch of Sinovac’s phase-three Covid-19 vaccine trials for use in children. The trial, which is taking place around the world, will see some 2,000 children and adolescents aged six months to 17 years enrolled to test the safety and efficacy of the CoronaVac jab. Globally, the trial will enrol 14,000 people, in Chile, the Philippines, Malaysia, Kenya, and South Africa.

The CoronaVac shot is not yet used in South Africa. In July, SAHPRA, the country’s drug regulator, provided conditional authorization for use of the vaccine in those aged between 18 and 59 years. In August, a senior health official told Reuters that the government needed more information from Sinovac, especially concerning efficacy against the Delta variant and in HIV-positive populations.

Concerns have been raised about the efficacy of the Chinese shot. Developers have suggested a third jab might be needed, with the additional shot raising efficacy to 82%. 

South Africa has one of the fastest inoculation programs on the continent, with around 17% of the population having received one shot.

Like this story? Share it with a friend!

source: RT




Împotriva articolelor redacției noastre, persoanele nemulțumite pot formula Contestație în termen de 10 zile de la publicarea articolului, la judecătoria Orășenească nr. 1 München Bayern Deutschland, in conformitate cu Legea federală Germană. Considerăm că nu se pot formula acțiuni la instanțele din România deoarece nici o persoană care activează în trustul nostru nu poate fi extrasă de sub jurisdicția federală germană. Considerăm că redacția noastră nu răspunde în fața autorităților din România ci doar celor federale sau civile germane. deoarece legea română nu are efecte de extraneitate asupra redacției chiar dacă subiectul știrilor face obiectul unor evenimente sau persoane din România și sunt scrise în limba română. Limba română nu este izvor de extraneitate a legii.

(Visited 15 times, 1 visits today)
Avatar
Marius Leontiuc
absolvent WEB DESIGN Academia Britanică de Comunicare Iasi - absolvent COMUNICARE IN AFACERI Academia Britanica de Afaceri si Comunicare -absolvent JURNALISM EDITORIAL - London School University - 2019 inscris la echivalare diploma la Universitatea Politehnica Timisoara - absolvent studii de Drept Universitatea Europeană Drăgan, cursuri in Drept la Universitatea de Vest Timisoara, absolvent studii de proiectare, pastor coordonator in Biserica Protestanta Evanghelica, Android Developer pe Google Play și plugin developer la Oxwall, creator de teme Wordpress și Oxwall, operator Wordpress, Drupal, Oxwall, Osclass, Moodle, tehnologii HTML și PHP
http://www.leontiucmarius.wordpress.com/cv

Lasă un răspuns

Adresa ta de email nu va fi publicată. Câmpurile obligatorii sunt marcate cu *